The evolving treatment paradigm of multiple myeloma: From past to present and future

Meral Beksaç1, Michel Delforge, Paul Richardson

  • 1Ankara University, Medical School, Hematology Department, Ankara, Turkey, Tel: +90 312 595 73 45

Insights

Multiple myeloma treatments have advanced, offering better disease control but not a cure. Ongoing research is crucial for addressing treatment challenges and improving outcomes for this complex blood cancer.

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Multiple myeloma, a malignancy of plasma cells, has been known since the mid-19th century.
  • Therapeutic strategies for multiple myeloma have evolved significantly over time.
  • Despite advances, achieving a complete cure for multiple myeloma remains a significant challenge.

Purpose of the Study:

  • To review the recent successes in multiple myeloma treatment.
  • To identify the limitations and drawbacks of current therapeutic approaches.
  • To highlight potential future solutions and research directions for managing multiple myeloma.

Main Methods:

  • Literature review of recent advancements in multiple myeloma therapy.
  • Analysis of clinical trial outcomes and treatment efficacy data.
  • Discussion of emerging therapeutic strategies and personalized medicine.

Main Results:

  • Recent therapies have improved disease control in multiple myeloma patients.
  • Current treatment regimens still face challenges related to drug resistance and toxicity.
  • Individual patient variations necessitate tailored treatment approaches.

Conclusions:

  • While significant progress has been made, a cure for multiple myeloma is not yet attainable.
  • Addressing the drawbacks of current treatments is essential for future therapeutic development.
  • Continuous research and updating of treatment information are vital for optimizing patient care in multiple myeloma.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K